Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors
Formylchromone inhibits a human protein tyrosine phosphatase PTP1B with a IC50 value of
73 μM. The chemical reactivity of formylchromone was adjusted by substitution at various
positions of the formylchromone skeleton. In an initial assessment of the structure–activity
relationship, the most potent inhibitor showed an IC50 of 4.3 μM against PTP1B and strong
or medium selectivity against other human PTPases, LAR and TC-PTP. This compound,
however, was not selective against microbial PTPases, YPTP1 and YOP. The potency and …
73 μM. The chemical reactivity of formylchromone was adjusted by substitution at various
positions of the formylchromone skeleton. In an initial assessment of the structure–activity
relationship, the most potent inhibitor showed an IC50 of 4.3 μM against PTP1B and strong
or medium selectivity against other human PTPases, LAR and TC-PTP. This compound,
however, was not selective against microbial PTPases, YPTP1 and YOP. The potency and …
Formylchromone inhibits a human protein tyrosine phosphatase PTP1B with a IC50 value of 73 μM. The chemical reactivity of formylchromone was adjusted by substitution at various positions of the formylchromone skeleton. In an initial assessment of the structure–activity relationship, the most potent inhibitor showed an IC50 of 4.3 μM against PTP1B and strong or medium selectivity against other human PTPases, LAR and TC-PTP. This compound, however, was not selective against microbial PTPases, YPTP1 and YOP. The potency and selectivity of the formylchromone derivatives expecting further improvements provides a novel pharmacophore for the design of drugs for the treatmenrt of type 2 diabetes and obesity.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果